George R. Brokaw
George R. Brokaw's purchase track record
How the stock did after each of George R. Brokaw's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/18/2025 | ECHO | $68K | +62.0% | +95.8% | +11.1% |
| 6/26/2025 | CTO | $34K | -5.6% | +8.6% | +12.8% |
| 6/13/2022 | CTO | $60K | +6.2% | -2.4% | +6.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
CTO Realty Announces Q3 2026 Earnings Release. CTO Realty Growth Inc. has announced the release date for its third‑quarter 2026 earnings and the schedule of the accompanying conference call. A recent article highlighted several factors that analysts view as positive for the company, including its dividend yield and valuation relative to peers. The announcement comes as the stock sits near its 200‑day moving‑average support level and its RSI is in the lower mid‑range. Investors will be watching the earnings results for guidance on future performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EchoStar upgraded to Overweight by JP Morgan, sees pre‑market move. JP Morgan raised EchoStar to Overweight and set a $144 price target, which sparked pre‑market activity noted in recent market scans. Analysts also highlighted the broader telecom sector as SpaceX’s Starlink Mobile plans and other satellite initiatives draw attention to companies like EchoStar. The stock is currently near a long‑standing support level that has been tested repeatedly.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Alico Highlighted as Unexpected Dividend Payer. Alico Inc. was named in a Yahoo article as one of four companies that pay dividends unexpectedly. The company’s dividend yield is 0.73%, which is modest compared to its high trailing P/E of 185.3. The article notes that investors often overlook such dividend payers, even though Alico’s price is close to its 52‑week high of $45.01.
Transaction History
| CC | ▲ Buy | Grant | 7,182 | $0 | 5/6/2026 | View on chart |
| CTO | ▲ Buy | Grant | 3,462 | $62K | 2/11/2026 | View on chart |
| ECHO | ▲ Buy | Option Exercise | 1,754 | $162K | 12/10/2025 | View on chart |
| ECHO | ▲ Buy | Open Market | 1,000 | $68K | 11/18/2025 | View on chart |
| CTO | ▲ Buy | Grant | 1,103 | $20K | 7/1/2025 | View on chart |
| CTO | ▲ Buy | Open Market | 2,000 | $34K | 6/26/2025 | View on chart |
| CC | ▲ Buy | Grant | 14,096 | $0 | 4/22/2025 | View on chart |
| ALCO | ▲ Buy | Grant | 681 | $0 | 4/1/2025 | View on chart |
| CTO | ▲ Buy | Grant | 1,055 | $20K | 4/1/2025 | View on chart |
| CTO | ▲ Buy | Grant | 3,185 | $62K | 2/12/2025 | View on chart |
| ALCO | ▲ Buy | Grant | 724 | $0 | 1/2/2025 | View on chart |
| CTO | ▲ Buy | Grant | 1,000 | $20K | 1/2/2025 | View on chart |
| ALCO | ▲ Buy | Grant | 684 | $0 | 10/1/2024 | View on chart |
| CTO | ▲ Buy | Grant | 1,040 | $20K | 10/1/2024 | View on chart |
| ALCO | ▲ Buy | Grant | 719 | $0 | 7/1/2024 | View on chart |
| CTO | ▲ Buy | Grant | 1,139 | $20K | 7/1/2024 | View on chart |
| ALCO | ▲ Buy | Grant | 640 | $0 | 4/1/2024 | View on chart |
| CTO | ▲ Buy | Grant | 1,186 | $20K | 4/1/2024 | View on chart |
| CTO | ▲ Buy | Grant | 3,740 | $62K | 2/14/2024 | View on chart |
| ALCO | ▲ Buy | Grant | 639 | $0 | 1/2/2024 | View on chart |
| CTO | ▲ Buy | Grant | 867 | $15K | 1/2/2024 | View on chart |
| ECHO | ▲ Buy | Grant | 1,754 | — | 12/31/2023 | View on chart |
| ALCO | ▲ Buy | Grant | 755 | $0 | 10/2/2023 | View on chart |
| CTO | ▲ Buy | Grant | 899 | $15K | 10/2/2023 | View on chart |
| ALCO | ▲ Buy | Grant | 731 | $0 | 7/3/2023 | View on chart |
| CTO | ▲ Buy | Grant | 894 | $15K | 7/3/2023 | View on chart |
| ALCO | ▲ Buy | Grant | 778 | $0 | 4/3/2023 | View on chart |
| CTO | ▲ Buy | Grant | 900 | $15K | 4/3/2023 | View on chart |
| CTO | ▲ Buy | Grant | 1,826 | $35K | 2/16/2023 | View on chart |
| ALCO | ▲ Buy | Grant | 787 | $19K | 1/3/2023 | View on chart |
| CTO | ▲ Buy | Grant | 808 | $15K | 1/3/2023 | View on chart |
| CTO | ▼ Sell | Other | 10,000 | $190K | 12/5/2022 | View on chart |
| ALCO | ▲ Buy | Grant | 637 | $19K | 10/3/2022 | View on chart |
| CTO | ▲ Buy | Grant | 755 | $15K | 10/1/2022 | View on chart |
| ALCO | ▲ Buy | Grant | 526 | $19K | 7/1/2022 | View on chart |
| CTO | ▲ Buy | Grant | 734 | $15K | 7/1/2022 | View on chart |
| CTO | ▲ Buy | Open Market | 1,000 | $60K | 6/13/2022 | View on chart |
| ALCO | ▲ Buy | Grant | 494 | $19K | 4/1/2022 | View on chart |
| CTO | ▲ Buy | Grant | 233 | $15K | 4/1/2022 | View on chart |
| CTO | ▲ Buy | Grant | 582 | $35K | 2/17/2022 | View on chart |
| ALCO | ▲ Buy | Grant | 498 | $19K | 1/3/2022 | View on chart |
| CTO | ▲ Buy | Grant | 262 | $15K | 1/3/2022 | View on chart |
| ALCO | ▲ Buy | Grant | 546 | $19K | 10/1/2021 | View on chart |
| CTO | ▲ Buy | Grant | 275 | $15K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Chemours Q2 Earnings Call and UBS Price Target Cut
Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.
Chemours Q2 Earnings Call and UBS Price Target Cut. Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.